A consolidated analysis of a phase I dose-escalation study (NCT02881138) and a parallel open-label phase Ib trial (NCT03052634) showed that HER2-positive breast cancer patients achieved an objective response rate (ORR) of 31.4%, along with a median progression-free survival (PFS) of 5.8 months (9, 10). Here, ERBB2 is linked to breast carcinoma.